Annual report pursuant to Section 13 and 15(d)

Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.19.1
Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Finite-lived Intangible Assets, Accumulated Amortization $ (13,767) $ (10,515)
Finite-lived Intangible Assets, Net Carrying Value $ 29,853 $ 33,105
Diagnostic Assets, Thyroid [Member] | Asuragen Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years 9 years
Finite-lived Intangible Assets, Gross $ 8,519 $ 8,519
Diagnostic Assets, Pancreas Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 7 years 7 years
Finite-lived Intangible Assets, Gross $ 16,141 $ 16,141
Diagnostic Assets, Barrett's Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years 9 years
Finite-lived Intangible Assets, Gross $ 18,351 $ 18,351
Diagnostic Lab, CLIA Lab [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days 2 years 3 months 19 days
Finite-lived Intangible Assets, Gross $ 609 $ 609
Diagnostic Assets [Member]    
Finite-lived Intangible Assets, Gross $ 43,011 $ 43,011